104 related articles for article (PubMed ID: 8821199)
1. Serum soluble interleukin 2 receptor in hemodialysis patients treated with recombinant human erythropoietin.
Sennesael JJ; Demanet CG; Verbeelen DL
Blood Purif; 1995; 13(6):347-56. PubMed ID: 8821199
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients.
Altun B; Erdem Y; Haznedaroğlu I; Gürsoy M; Yasavul U; Turgan C; Cağlar S; Kirazli S
Nephrol Dial Transplant; 1995 Nov; 10(11):2164. PubMed ID: 8643199
[No Abstract] [Full Text] [Related]
3. Soluble interleukin-2 receptors in the serum of patients with chronic renal failure.
Takamatsu T; Yasuda N; Ohno T; Kanoh T; Uchino H; Fujisawa A
Tohoku J Exp Med; 1988 Aug; 155(4):343-7. PubMed ID: 3068834
[TBL] [Abstract][Full Text] [Related]
4. Lack of influence of recombinant human erythropoietin on parathyroid function in hemodialysis patients with secondary hyperparathyroidism.
Lai YH; Tsai JC; Chen HC; Guh JY; Hwang SJ; Tsai JH
Nephron; 1995; 70(2):223-8. PubMed ID: 7566308
[TBL] [Abstract][Full Text] [Related]
5. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
Fishbane S; Berns JS
Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
[TBL] [Abstract][Full Text] [Related]
7. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
8. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
Tarng DC; Huang TP; Doong TI
Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
[TBL] [Abstract][Full Text] [Related]
9. Anemia of chronic renal failure: treatment with erythropoietin.
Navarro M; Alonso A; Avilla JM; Espinosa L
Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
[TBL] [Abstract][Full Text] [Related]
10. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
Tarng DC; Huang TP; Chen TW
Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin.
Roman RM; Lobo PI; Taylor RP; Goodkin DA; LaBrecque J; Powers KL; Bolton WK
J Am Soc Nephrol; 2004 May; 15(5):1339-46. PubMed ID: 15100375
[TBL] [Abstract][Full Text] [Related]
12. Randomized prospective comparison between erythropoietin and androgens in CAPD patients.
Navarro JF; Mora C; Macía M; García J
Kidney Int; 2002 Apr; 61(4):1537-44. PubMed ID: 11918762
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation.
Van Biesen W; Vanholder R; Veys N; Verbeke F; Lameire N
Transplantation; 2005 Feb; 79(3):367-8. PubMed ID: 15699772
[TBL] [Abstract][Full Text] [Related]
14. Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study.
Nafar M; Samavat S; Khoshdel A; Alipour-Abedi B
Iran J Kidney Dis; 2017 Jan; 11(1):56-65. PubMed ID: 28174354
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
16. Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients.
Cheng IK; Lu HB; Wei DC; Cheng SW; Chan CY; Lee FC
Am J Nephrol; 1993; 13(2):142-8. PubMed ID: 8342581
[TBL] [Abstract][Full Text] [Related]
17. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients.
Roberts TL; Obrador GT; St Peter WL; Pereira BJ; Collins AJ
Kidney Int; 2004 Dec; 66(6):2429-36. PubMed ID: 15569336
[TBL] [Abstract][Full Text] [Related]
18. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
19. Does parathyroid hormone affect erythropoietin therapy in dialysis patients?
Al-Hilali N; Al-Humoud H; Ninan VT; Nampoory MR; Puliyclil MA; Johny KV
Med Princ Pract; 2007; 16(1):63-7. PubMed ID: 17159367
[TBL] [Abstract][Full Text] [Related]
20. [Subcutaneous administration of recombinant human erythropoietin (R-EPO) in the treatment of anemia in predialysis patients with chronic renal failure].
Debska-Slizień A; Rutkowski B; Niemierko J; Jankowska-Gan E; Gołebiewska-Zurkowska G; Kabata J; Manitius A
Pol Arch Med Wewn; 1991 Jun; 85(6):334-40. PubMed ID: 1896396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
